Dark

Check out our API

CUBT
CURATIVE BIOTECHNLOGY INC
stock OTC

EOD

Aug 4, 2026

1.15USD-12.548%(-0.17)1,825

Pre-market

0.00USD-100.000%(-1.48)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 24, 2021

03:05PM EST Companys First In-license Pipeline Product to Enter Pre-clinical Studies GlobeNewswire Inc

Oct 12, 2021

10:12AM EDT Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-relatedMacular Degeneration GlobeNewswire Inc

Oct 7, 2021

10:20AM EDT License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies GlobeNewswire Inc

09:45AM EDT Curative Biotechnology Announces IMT504 License For Development Of Proprietary PR Newswire

Sep 2, 2021

10:10AM EDT Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Expertise in Neurobiology GlobeNewswire Inc

Jul 15, 2021

10:00AM EDT Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of GlobeNewswire Inc

May 25, 2021

09:50AM EDT Curative Biotechnology, Inc. (OTC: CUBT) (Curative Biotech or the Company), a development-stage biomedical company targeting novel treatments for rare diseases, filed its Q1 quarterly reportfor the period ending March 31, 2021. The Q1 report can be viewed in its entirety at: GlobeNewswire Inc

Apr 29, 2021

10:12AM EDT Kapil Bharti, Ph.D.and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board GlobeNewswire Inc

09:30AM EDT Curative Biotechnology, Inc. Announces FINRA Ticker Symbol Change From "CTYX" PR Newswire

Share